Autism Treatments – Clinical Research Trials

Autism Treatments – Clinical Research Trials

clinical trials autism research participants

Ongoing UK Clinical Trials for Autism – research studies recruiting participants

The following is a list of research trials currently taking place in the UK and actively recruiting study participants. The studies have been designed to investigate the potential of various medications and interventions to help reduce core autism symptoms, and/or difficulties and symptoms frequently experienced by individuals affected by autism such as anxiety, irritability, impulsive, aggressive and self-harming and other challenging behaviours.

Please note that the studies are not run by Thinking Autism. We can not reply to questions about the studies, the treatments themselves, or your or your child’s eligibility to take part in the trials. If you have any questions about the trials or would like your child/ren or yourself to take part in one of the studies please contact the institutions that are running the trials via the links provided.

Please note: the list is not comprehensive. If your organisation is running a trial and recruiting participants who live in the UK please contact us to have it added to the list. In order to qualify for a listing the aims and objectives of the study need to fall under one or both of the following categories: 1. reducing core symptoms of autism 2. addressing underlying or comorbid biomedical disorders that contribute to symptoms and difficulties experienced by individuals with autism.

The list will be updated on an ongoing basis. Please make sure to come back and refresh the page from time to time, or subscribe to our mailing list to be informed of future additions.

Bumetanide for Autism treatment trial (ongoing)

A large European multi-centre Phase III trial is currently taking place in France and several other EU countries, including the UK.

This study is investigating the effectiveness of bumetanide for treating core symptoms of autism. Children and adolescents with a diagnosis of autism or suspected diagnosis, aged 2-17 years can participate.

UK centres conducting the trials:

ReCognition Health (several recruitment centres in the UK) – click here for more details and to apply

 

More details and results of previous bumetanide autism trials

Balovaptan for Autism – a Multicentre Clinical Trial For Adults (LONDON & UK)

Re:Cognition Health are currently recruiting patients aged 18+ for an adult autism clinical trial

The award-winning team at Re:Cognition Health are delighted to be launching new clinical trials for adult autism to find new medications to help individuals manage some of challenging symptoms such as helping with socialisation, stress, anxiety or aggression. To date, there are no approved medications that target these core symptoms and this clinical study aims to change this.

Adults with autism have a different sensory experience; seeing, hearing and feeling the world differently and they may sometimes find this challenging when socialising or communicating. This new trial is investigating whether an existing medicine can be repurposed can help individuals with autism manage those challenges.

The investigators are looking for adults (aged over 18) with a diagnosis of autism to take part in this clinical trial.

Contact Re:Cognition Health to register your interest in taking part in this trial.

For more information on the trial itself visit the official V1ADUCT trial page

The V1ADUCT clinical trial for social function in autism (SOUTH LONDON)

South London and Maudsley NHS Foundation Trust, provider of the widest range of mental health services in the UK, is looking for adults with autism to take part in a new drug trial.

Who can take part?

  • Do you have autism spectrum disorder?
  • Are you at least 18 years old?
  • Do you have someone you see and speak to regularly, who would be willing and able to be your ‘study partner’?

If so, you may be able to take part in V1ADUCT!

Thousands of people all around the world take part in clinical trials every year. Without them, new treatments cannot be developed. In fact, every medication that you’ve ever taken will have been investigated in clinical trials first.

V1ADUCT is assessing an investigational medication to see if it can help adults with autism better manage the social and communication challenges that are at the heart of autism. To date, no medications have been approved to treat autism’s core symptoms. By taking part in the study you will help us increase understanding of adult autism as well as have the opportunity to take part in a 2-year extension of the trial.

To find out more and to register your interest contact the V1ADUCT team by email [email protected] or call them on 0207 848 1520.

The V1ADUCT clinical trial for social function in autism (EDINBURGH)

The Patrick Wild Centre at the University of Edinburgh / NHS Lothian, is offering adults with autism the opportunity to take part in a trial of a new medicine.

The V1ADUCT study is assessing a new medication to see if it can help adults with autism better manage social and communication challenges.

To take part you need to:

  • Do you have autism spectrum disorder?
  • Are you at least 18 years old?
  • Do you have someone you see and speak to regularly, who would be willing and able to be your ‘study partner’?

To find out more contact the V1ADUCT team at the Patrick Wild Centre by email on [email protected] or call them on 0131 537 6265.

There are also sites in Glasgow and London so if you can’t make it to Edinburgh you may still be able to take part.

Arbaclofen for improving social difficulties in autism (launching summer 2019)

Part of the AIMS-2-TRIALS (Autism Innovative Medicine Studies-2-Trials). University of Newcastle, University of Edinburgh, University of Glasgow, King’s College London will taking part in a large treatment trial of arbaclofen. The medicine is thought to improve social difficulties in autism.

The study will be looking to recruit children and adolescents aged between 5 and 17 years of age who are verbal and/or able to give consent to trial (additional exclusion criteria will apply). The participants will need to live near or be able to travel to one of the recruitment centres.

Please note that this study is not yet recruiting participants. It is expected that the recruitment will start in late summer 2019. Watch this space for further information.

Information on AIMS-2 and arbaclofen

Thinking Autism blog – science news & updates

Transcranial direct current stimulation tDCS – a novel treatment for autism?

Transcranial direct current stimulation tDCS – a novel treatment for autism?

One of the treatment modalities that has shown the greatest promise for reducing symptoms of autism in recent years is transcranial direct current stimulation (tDCS). The most recent study confirmed and expanded on the findings of previous investigations, which strongly indicate that tDCS could have positive effects on cognition, behaviour and physical health, and improve quality of life and autonomy for a large percentage of individuals with autism.

read more
Cannabis for Treating Core and Comorbid Autism Symptoms – Where are we at?

Cannabis for Treating Core and Comorbid Autism Symptoms – Where are we at?

Several studies published in recent months investigated the effects of cannabis-based products for treating autism. Although the studies were open-label and relatively small in scale, the overall results were overwhelmingly positive, with statistically significant improvements in social communication, language, restrictive/repetitive and challenging behaviours.

read more
Century-old drug offers new hope for autism treatment

Century-old drug offers new hope for autism treatment

A small double-blind, placebo-controlled trial shows dramatic effects of suramin as a treatment for autism. Improvements were seen in all three core features of autism: language, social interactions, and restricted or repetitive behaviours across multiple diagnostics in multiple tests in all who received the active treatments, absent in the placebo arm

read more
Higher rates of autism in children with various congenital disorders

Higher rates of autism in children with various congenital disorders

Children with Congenital Heart Disease, Tuberous Sclerosis Complex, Duchenne Muscular Dystrophy, Ehlers-Danlos Syndrome, Neurofibromatosis Type 1 suffer high rates of autism. Everolimus, an mTOR inhibitor with strong neuro-inflammation attenuating effects, reduces core autism symptoms in some children with TSC, epilepsy and autism…

read more
Diuretic drug improves core autism symptoms

Diuretic drug improves core autism symptoms

Double-blind randomized multicenter trial finds bumetanide ameliorates core symptoms of autism.A medical drug normally used to relieve fluid retention has been repurposed as a treatment for the core symptoms of autism. Following on from the promising results of their...

read more
ACTH therapy benefits stuttering and autism

ACTH therapy benefits stuttering and autism

Adrenocorticotropic hormone therapy in patients with nighttime subclinical seizure activity improves their stuttering and autism symptoms ACTH therapy improves core symptoms of autism alongside EEG parameters and sublinical seizures. In a retrospective study a total...

read more
DISCLAIMER The purpose of this site is to provide information. No information on this website should be construed as medical advice. Neither article authors, associated charities, nor individual contributors take any responsibility or liability for any decision taken by site visitors as a result of the information contained herein or the external links provided. If you need medical advice, please seek it from a suitably qualified practitioner.

Privacy Policy  |  Terms and Conditions
© 2019 Thinking Autism | All rights reserved | Registered Charity: No. 1113628, Limited Company Registered in England: No. 5594787 | Registered address: International House, 24 Holborn Viaduct, London, EC1A 2BN | Contact tel. 07518131697